---
title: "Tivic Health Systems rises after deal for late-stage immunotherapy drug"
date: "2025-02-13 03:22:07"
summary: "** Shares of medical device maker Tivic Health Systems more than double to 49 cents; set to record the largest single-day percentage gain** TIVC says it has acquired exclusive worldwide rights from Statera Biopharma to a late-stage immunotherapy drug called entolimod, which is used for the treatment of acute radiation..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* Shares of medical device maker Tivic Health Systems more than double to 49 cents; set to record the largest single-day percentage gain

\*\* TIVC says it has acquired exclusive worldwide rights from Statera Biopharma to a late-stage immunotherapy drug called entolimod, which is used for the treatment of acute radiation syndrome (ARS), a condition caused by exposure to high doses of ionizing radiation

\*\* The deal includes an initial payment of $1.2 million in equity and $300,000 in cash to Statera

\*\* Drug has the potential to be approved by the U.S. FDA within two years - TIVC

\*\* The FDA has granted "fast track" and "orphan drug" designation to entolimod for the treatment of ARS - TIVC

\*\* The global ARS market is estimated to be valued at $5.2 billion in 2024 with a compound annual growth rate of 5% from 2024 to 2031 - TIVC

\*\* TIVC fell 80.7% in 2024

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P31LD:0-tivic-health-systems-rises-after-deal-for-late-stage-immunotherapy-drug/)
